Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Delineating somatostatin's neuronal actions.

A D Blake1, A C Badway, M Z Strowski

  • 1Dept of Biology, Seton Hall University, South Orange, NJ 07079, USA. blakeall@shu.edu

Current Drug Targets. CNS and Neurological Disorders
|April 14, 2004
PubMed
Summary

Somatostatin (SRIF) actions are mediated by five receptor subtypes (sst1-5). New tools like subtype-selective ligands and gene knockout models are clarifying the specific roles of these somatostatin receptors in the nervous system.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neuropeptide B promotes differentiation of rodent white preadipocytes into mature adipocytes.

Molecular and cellular endocrinology·2023
Same author

The role of orexin in controlling the activity of the adipo-pancreatic axis.

The Journal of endocrinology·2018
Same author

Chronic orexin-A (hypocretin-1) treatment of type 2 diabetic rats improves glucose control and beta-cell functions.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2018
Same author

Serum levels of spexin and kisspeptin negatively correlate with obesity and insulin resistance in women.

Physiological research·2017
Same author

TRPV4 regulates insulin mRNA expression and INS-1E cell death via ERK1/2 and NO-dependent mechanisms.

Cellular signalling·2017
Same author

Orexin A modulates INS-1E cell proliferation and insulin secretion via extracellular signal-regulated kinase and transient receptor potential channels.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2016

Area of Science:

  • Neurobiology
  • Endocrinology
  • Pharmacology

Background:

  • Somatostatin (SRIF) is a peptide hormone that regulates numerous physiological processes through its interaction with five distinct receptor subtypes (sst1-5).
  • SRIF's actions in the nervous system involve regulating protein phosphorylation, second messenger production, and neuronal membrane potential.
  • Understanding the specific roles of each SRIF receptor subtype has been challenging due to overlapping expression patterns and potential receptor oligomerization.

Purpose of the Study:

  • To delineate the distinct neuronal roles of each somatostatin receptor subtype.
  • To leverage recent advancements in pharmacological and molecular tools to advance SRIF neurobiology.
  • To explore potential therapeutic avenues based on a clearer understanding of SRIF receptor function.

Main Methods:

  • Utilizing SRIF receptor subtype-specific antibodies to map receptor expression patterns.
  • Employing newly developed SRIF receptor subtype-selective ligands for in vitro and in vivo studies.
  • Generating and analyzing in vitro and in vivo models with inactivated SRIF receptor genes.

Main Results:

  • SRIF receptor subtypes exhibit complex and overlapping expression patterns in the central and peripheral nervous systems.
  • Receptor homo- and heteroligomerization may contribute to the complexity of SRIF signaling.
  • Selective ligands and gene knockout models are beginning to differentiate the functions of individual SRIF receptor subtypes.

Conclusions:

  • Recent pharmacological, immunological, and molecular approaches are enhancing our understanding of somatostatin neurobiology.
  • The distinct roles of SRIF receptor subtypes are becoming clearer, paving the way for targeted therapeutic strategies.
  • Further research promises new treatments for conditions involving dysregulated somatostatin signaling.

Related Experiment Videos